PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease-Reference-Cited by-同舟云学术

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

Published:2020-10-20 Issue:12 Volume:2020 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Schmidt Amand F¹²,Carter John-Paul L³,Pearce Lucy S⁴,Wilkins John T⁵,Overington John P⁶,Hingorani Aroon D¹,Casas JP⁷

Affiliation:

1. Institute of Cardiovascular Science; University College London; London UK

2. Department of Cardiology, Division Heart and Lungs; UMC Utrecht; Utrecht Netherlands

3. Department of Clinical Pharmacology and Therapeutics; University College London Hospital; London UK

4. Department of Non-communicable Disease Epidemiology; London School of Hygiene & Tropical Medicine; London UK

5. The Department of Medicine (Cardiology) and the Department of Preventive Medicine; Northwestern University Feinberg School of Medicine; Chicago Illinois USA

6. Medicines Discovery Catapult; Alderly Edge UK

7. Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC); VA Boston Healthcare System; Boston Massachusetts USA

Publisher

Wiley

Subject

Pharmacology (medical)

Reference118 articles.

1. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia;Blom;New England Journal of Medicine,2014

2. Evolocumab and clinical outcomes in patients with cardiovascular disease;Sabatine;New England Journal of Medicine,2017

3. Efficacy and tolerability of evolocumab vs ezetimibein patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial;Nissen;JAMA,2016

4. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial;Nicholls;JAMA,2016

5. Effect of evolocumab on coronary plaque composition;Nicholls;Journal of the American College of Cardiology,2018

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dynamic trends of ischemic heart disease mortality attributable to high low-density lipoprotein cholesterol: a joinpoint analysis and age-period-cohort analysis with predictions;Lipids in Health and Disease;2024-09-11

2. Chronic coronary syndromes: diagnosis, management and gaps in evidence;Heart, Vessels and Transplantation;2024-08-28

3. PCSK9 inhibition: from effectiveness to cost-effectiveness;Frontiers in Cardiovascular Medicine;2024-06-25

4. Quantitative assessment of baseline imbalances in evolocumab and alirocumab trials: a meta-epidemiological study;BMC Medical Research Methodology;2024-06-22

5. Effect of adding PCSK9 inhibitors to lipid‐lowering interventions on arterial stiffness: A systematic review and meta‐analysis;European Journal of Clinical Investigation;2024-06-21